PERNIX THERAPEUTICS HOLDINGS, INC. - FORM 8-K - EX-4.4 - SECOND SUPPLEMENTAL INDENTURE - August 22, 2014

Attached files

file filename
8-K - CURRENT REPORT - PERNIX THERAPEUTICS HOLDINGS, INC.ptx_8k.htm
EX-4.1 - INDENTURE - PERNIX THERAPEUTICS HOLDINGS, INC.ptx_ex41.htm
EX-4.2 - FORM OF 12% NOTE - PERNIX THERAPEUTICS HOLDINGS, INC.ptx_ex42.htm
EX-4.3 - FIRST SUPPLEMENTAL INDENTURE - PERNIX THERAPEUTICS HOLDINGS, INC.ptx_ex43.htm
EX-10.2 - PURCHASE PRICE REDUCTION AND AGREEMENT AMENDMENTS - PERNIX THERAPEUTICS HOLDINGS, INC.ptx_ex102.htm
EX-99.1 - PERNIX THERAPEUTICS HOLDINGS, INC.ptx_ex991.htm
EX-10.1 - AMENDMENT NO. 3 TO AMENDED AND RESTATED CREDIT AGREEMENT - PERNIX THERAPEUTICS HOLDINGS, INC.ptx_ex101.htm
Exhibit 4.4
 

 

 

 

 

 

 
PERNIX THERAPEUTICS HOLDINGS, INC.
 
AND
 
WORRIGAN LIMITED, as a Guarantor
 
AND
 
WILMINGTON TRUST, NATIONAL ASSOCIATION,
 
 
as Trustee
 
SECOND SUPPLEMENTAL INDENTURE
 
Dated as of August 19, 2014
 
8.00% Convertible Senior Notes due 2019
 

 

 

 
 
 
 
 
THIS SECOND SUPPLEMENTAL INDENTURE (this "Second Supplemental Indenture"), entered into as of August 19, 2014, among Pernix Therapeutics Holdings, Inc., a Maryland corporation (the "Company"), Worrigan Limited, a private limited liability company formed in the Republic of Ireland ("Worrigan Limited") and Wilmington Trust, National Association, a national banking association (the "Trustee").
 
RECITALS
 
WHEREAS, the Company, the other Guarantors party thereto and the Trustee entered into an indenture, dated as of February 21, 2014 (the "Indenture"), relating to the Company's 8.00% Convertible Senior Notes due 2019 (the "Notes"); and
 
WHEREAS, as a condition to the purchase of the Notes by the Holders, the Company agreed pursuant to the Indenture to cause certain Subsidiaries from time to time to provide Guarantees.
 
AGREEMENT
 
NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and intending to be legally bound, the parties hereto hereby agree as follows:
 
Section 1.  Capitalized terms used herein and not otherwise defined herein are used as defined in the Indenture.
 
Section 2.  Worrigan Limited, by its execution of this Second Supplemental Indenture, agrees to be a Guarantor under the Indenture and to be bound by the terms of the Indenture applicable to Guarantors, including, but not limited to, Article 13 thereof.
 
Section 3.  This Second Supplemental Indenture shall be governed by and construed in accordance with the laws of the State of New York.
 
Section 4.  This Second Supplemental Indenture may be signed in various counterparts which together shall constitute one and the same instrument.
 
Section 5.  This Second Supplemental Indenture is an amendment supplemental to the Indenture and the First Supplemental Indenture, and the Indenture, the First Supplemental Indenture and this Second Supplemental Indenture shall henceforth be read together.
 
Section 6.  The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the Recitals contained herein, all of which are made solely by the Company and Worrigan Limited.
 

 
[Signatures on Next Page]
 
 
 
2
 
 
 
IN WITNESS WHEREOF, the parties hereto have caused this Second Supplemental Indenture to be duly executed as of the date first above written.
 
 
PERNIX THERAPEUTICS HOLDINGS, INC.
 
By: /s/ Douglas Drysdale
Name: Douglas Drysdale
Title:   Chief Executive Officer
  
 
PRESENT when the Common
Seal of Worrigan Limited was
affixed hereto and this deed
was delivered:
                   (SEAL)
  
WORRIGAN LIMITED
 
By: /s/ Douglas Drysdale
Name: Douglas Drysdale
Title:   Chief Executive Officer
  
 
 
WILMINGTON TRUST, NATIONAL
ASSOCIATION, as Trustee
 
By: /s/ Lynn M. Steiner
Name: Lynn M. Steiner
 Title:   Vice President
  
 
 
3
 

PERNIX THERAPEUTICS HOLDINGS, INC. Reports